OBIO Orchestra BioMed (OBIO) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001814114
Cluster · 4 insidersC-suite buying · 2Form 144 · 3
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
47
13F, latest reported quarter
What the filings say about OBIO
Insiders, 180 days
-$136.3K net sold
4 buyers · 1 seller · 40% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$230.6K
3 notices
Orchestra BioMed insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Orchestra BioMed Holdings, Inc. insiders sold a net $136.3K of stock across 47 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 11 earlier Form 4 trades (code P or S) here by this insider (2 buys, 9 sales), the last on Sep 1, 2026.
- The trade is 1.3% of the 1,119,402 shares held after it.
- No other insider sold within 30 days.
- 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Sherman Darren sold about $95.4K of OBIO under a 10b5-1 plan on Oct 1, 2026, the largest insider sale at the company on our record; 47 funds added in the latest 13F quarter.Context
- 17 earlier Form 4 trades (code P or S) here by this insider (17 buys), the last on Jun 1, 2026.
- +2.0% median (+12.3% mean) 90-day return after 14 previous buys.
- The trade is 0.9% of the 1,070,746 shares held after it.
- 1 other insider bought within 30 days.
- 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Hochman David P bought about $47.9K of OBIO on Sep 3, 2026; 1 other insider bought within 30 days and 47 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (2 buys, 8 sales), the last on Aug 26, 2026.
- The trade is 1.3% of the 1,134,402 shares held after it.
- No other insider sold within 30 days.
- 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Sherman Darren sold about $74.1K of OBIO under a 10b5-1 plan on Sep 1, 2026, the largest insider sale at the company on our record; 47 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (1 buy, 8 sales), the last on Aug 3, 2026.
- The trade is 100.0% of the 2,000 shares held after it.
- 1 other insider bought within 30 days.
- 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Sherman Darren bought about $10.7K of OBIO on Aug 26, 2026; 1 other insider bought within 30 days and 47 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (1 buy, 7 sales), the last on Jul 1, 2026.
- The trade is 1.3% of the 1,154,327 shares held after it.
- No other insider sold within 30 days.
- 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Sherman Darren sold about $61.4K of OBIO on Aug 3, 2026; 47 funds added in the latest 13F quarter.47 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$136.3K over 180 days
-$172.3K over 90 days
more than 52% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
47 funds bought in last quarter
below 59% of Medical Devices
Revenue
+1169.2% year over year
the highest in Medical Devices
Margin
-157.4% net margin
below 83% of Medical Devices
Buybacks
no share repurchases reported
Short interest
7.8% of the float short (float per yahoo 2026-10-27) · 9.7 days to cover · settled 2026-10-15
more than 60% of Medical Devices
What changed in the last 30 days
Oct 2See Remarks Sherman Darren sold $95.4K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Officer Sherman Darren filed to sell $94.0K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch OBIO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+46.1%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns OBIO: institutional holders (13F)
13F holdings, latest reported quarter
9,556,063 sh
$41.2M
5,037,906 sh
$21.7M
2,510,387 sh
$10.8M
2,022,916 sh
$8.7M
1,007,908 sh
$4.4M
Congress trades in OBIO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
OBIO planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Sherman Darren
Filed 2026-10-01
$94.0K
Sherman Darren
Filed 2026-09-01
$75.3K
Sherman Darren
Filed 2026-08-03
$61.3K
Sherman Darren
Filed 2026-07-01
$64.8K
OBIO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$946.7K position · as of 2026-06-30
1.2%
Ultra-Small Company Market Fund
$317.2K position · as of 2026-06-30
0.2%
Clearwater Select Equity Fund
$372.9K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$577.2K position · as of 2026-06-30
0.0%
GuideMark Small/Mid Cap Core Fund
$21.4K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$39.0K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $136.3K sold by insiders over 180 days, 47 funds added last quarter, $230.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
OBIO financials
Revenue growth
+1169.2%
XBRL, annual
Net margin
-157.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$32.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM OBIO
| FY Dec 2025 | $33.5M |
| FY Dec 2024 | $2.6M |
| FY Dec 2023 | $2.8M |
| FY Dec 2022 | $3.5M |
| FY Dec 2021 | n/a |
| Jun 2026 | $88.0K |
| Mar 2026 | $110.0K |
| Dec 2025 | $30.9M |
| Sep 2025 | $861.0K |
| Jun 2025 | $836.0K |
| Mar 2025 | $868.0K |
| Dec 2024 | $253.0K |
| Sep 2024 | $987.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-184.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM OBIO
| FY Dec 2025 | -157.4% |
| FY Dec 2024 | -2,313% |
| FY Dec 2023 | -1,780% |
| FY Dec 2022 | -951.3% |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | +20.2% |
| Sep 2025 | -2,419% |
| Jun 2025 | -2,316% |
| Mar 2025 | -2,161% |
| Dec 2024 | -6,385% |
| Sep 2024 | -1,563% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$59.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM OBIO
| FY Dec 2025 | -$49.5M |
| FY Dec 2024 | -$50.8M |
| FY Dec 2023 | -$46.2M |
| FY Dec 2022 | -$29.9M |
| FY Dec 2021 | n/a |
| Jun 2026 | -$19.6M |
| Mar 2026 | -$22.4M |
| Dec 2025 | -$2.3M |
| Sep 2025 | -$14.9M |
| Jun 2025 | -$15.6M |
| Mar 2025 | -$16.7M |
| Dec 2024 | -$13.6M |
| Sep 2024 | -$13.8M |
At each fiscal year end
Single quarter
Debt to equity
0.78x
long-term debt only, 2026-03-31; equity 2026-06-30
Debt to equity OBIO
| FY Dec 2025 | 0.28x |
| FY Dec 2024 | 0.46x |
| FY Dec 2023 | 0.15x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.78x |
| Mar 2026 | 0.36x |
| Dec 2025 | 0.28x |
| Sep 2025 | 0.34x |
| Jun 2025 | 50.85x |
| Mar 2025 | 0.89x |
| Dec 2024 | 0.46x |
| Sep 2024 | 0.22x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-3.89x
TTM operating cash flow over long-term debt only, 2026-03-31
Cash flow to debt OBIO
| FY Dec 2025 | -3.26x |
| FY Dec 2024 | -3.37x |
| FY Dec 2023 | -4.61x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -3.89x |
| Mar 2026 | -3.63x |
| Dec 2025 | -3.26x |
| Sep 2025 | -4.02x |
| Jun 2025 | -3.96x |
| Mar 2025 | -3.60x |
| Dec 2024 | -3.37x |
| Sep 2024 | -4.80x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-601.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity OBIO
| FY Dec 2025 | -121.8% |
| FY Dec 2024 | -120.8% |
| FY Dec 2023 | -81.5% |
| FY Dec 2022 | -205.2% |
| FY Dec 2021 | n/a |
| Jun 2026 | -601.8% |
| Mar 2026 | -188.2% |
| Dec 2025 | -121.8% |
| Sep 2025 | -167.0% |
| Jun 2025 | -313.8% |
| Mar 2025 | -179.1% |
| Dec 2024 | -120.8% |
| Sep 2024 | -91.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-74.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets OBIO
| FY Dec 2025 | -55.2% |
| FY Dec 2024 | -71.2% |
| FY Dec 2023 | -51.5% |
| FY Dec 2022 | -26.1% |
| FY Dec 2021 | -0.2% |
| Jun 2026 | -74.5% |
| Mar 2026 | -68.4% |
| Dec 2025 | -55.2% |
| Sep 2025 | -83.4% |
| Jun 2025 | -121.0% |
| Mar 2025 | -93.6% |
| Dec 2024 | -71.2% |
| Sep 2024 | -60.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital OBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-90.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed OBIO
| FY Dec 2025 | -65.5% |
| FY Dec 2024 | -89.3% |
| FY Dec 2023 | -64.0% |
| FY Dec 2022 | -27.4% |
| FY Dec 2021 | -0.2% |
| Jun 2026 | -90.6% |
| Mar 2026 | -84.2% |
| Dec 2025 | -65.5% |
| Sep 2025 | -105.0% |
| Jun 2025 | -170.4% |
| Mar 2025 | -118.9% |
| Dec 2024 | -89.3% |
| Sep 2024 | -78.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing OBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$328.1M
market value at close 2026-10-26 on 2026-08-06 shares, plus long-term debt only, 2026-03-31, minus cash 2026-06-30
Enterprise value OBIO
| FY Dec 2025 | $214.6M |
| FY Dec 2024 | $144.8M |
| FY Dec 2023 | $305.8M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $252.9M |
| Mar 2026 | $235.3M |
| Dec 2025 | $214.6M |
| Sep 2025 | $106.8M |
| Jun 2025 | $98.9M |
| Mar 2025 | $160.6M |
| Dec 2024 | $144.8M |
| Sep 2024 | $178.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-17.7%
TTM free cash flow over market value at close 2026-10-26
FCF yield OBIO
| FY Dec 2025 | -21.1% |
| FY Dec 2024 | -33.4% |
| FY Dec 2023 | -14.2% |
| FY Dec 2022 | -26.7% |
| FY Dec 2021 | n/a |
| Jun 2026 | -22.9% |
| Mar 2026 | -22.1% |
| Dec 2025 | -21.1% |
| Sep 2025 | -45.4% |
| Jun 2025 | -58.1% |
| Mar 2025 | -33.2% |
| Dec 2024 | -33.4% |
| Sep 2024 | -24.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing OBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $33.5M | $2.6M | $2.8M | $3.5M |
| Operating income | -$51.8M | -$64.3M | -$51.5M | -$32.7M |
| Net income | -$52.7M | -$61.0M | -$49.1M | -$33.6M |
| EPS (diluted) | -1.11 | -1.66 | -1.48 | -2.24 |
| Operating cash flow | -$49.0M | -$50.6M | -$46.1M | -$29.3M |
| Cash | $34.7M | $22.3M | $30.6M | $19.8M |
| Long-term debt | $15.0M | $15.0M | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
OBIO Stock Sonar score 6/7 axes
Find similar shapesCompareOBIO ranks highest on growth (98th percentile) and insider conviction (80th), and lowest on profitability (17th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
OBIO filings, in plain words
Are Orchestra BioMed insiders buying or selling OBIO?
In the 180 days to 2026-10-28, Orchestra BioMed insiders were net sellers, a net $136.3K: $216.6K of purchases and $352.9K of sales reported on Form 4, by 4 buyers and 1 seller.
Are there planned insider sales of OBIO?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $230.6K of stock; the latest, by Sherman Darren, was filed 2026-10-01.
Read the full summary
In the 180 days to 2026-10-28, Orchestra BioMed insiders were net sellers of OBIO, a net $136.3K across purchases and sales reported on Form 4 by 4 buyers and 1 seller. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. 40% of the 5 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $230.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
